ALNYLAM PHARMACEUTICALS, INC. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$595.00 thousand for the 9-month period ending 2011-09-30, per its 10-Q filed 2012-11-05.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2012-11-05
- 2011-09-30: Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month -$595.00K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month |
|---|---|
| 2011-09-30 | -$595.00K 10-Q · filed 2012-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |